C
Christina Nowack
Researcher at Bayer
Publications - 27
Citations - 3064
Christina Nowack is an academic researcher from Bayer. The author has contributed to research in topics: Finerenone & Kidney disease. The author has an hindex of 16, co-authored 24 publications receiving 1751 citations. Previous affiliations of Christina Nowack include Bayer HealthCare Pharmaceuticals & Bayer Corporation.
Papers
More filters
Journal ArticleDOI
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris,Rajiv Agarwal,Stefan D Anker,Bertram Pitt,Luis M. Ruilope,Peter Rossing,Peter Kolkhof,Christina Nowack,Patrick Schloemer,Amer Joseph,Gerasimos Filippatos,Fidelio-Dkd Investigators +11 more
TL;DR: In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo, and the frequency of adverse events was similar in the two groups.
Journal ArticleDOI
Effect of finerenone on albuminuria in patients with diabetic nephropathy : a randomized clinical trial
George L. Bakris,Rajiv Agarwal,Juliana C.N. Chan,Mark E. Cooper,Ron T. Gansevoort,Hermann Haller,Giuseppe Remuzzi,Peter Rossing,Roland E. Schmieder,Christina Nowack,Peter Kolkhof,Amer Joseph,Alexander Pieper,Nina Kimmeskamp-Kirschbaum,Luis M. Ruilope +14 more
TL;DR: Finerenone demonstrated a dose-dependent reduction in UACR, and among patients with diabetic nephropathy, the addition of finerenone compared with placebo resulted in improvement in the urinary albumin-creatinine ratio.
Journal ArticleDOI
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt,Lars Køber,Piotr Ponikowski,Mihai Gheorghiade,Gerasimos Filippatos,Henry Krum,Christina Nowack,Peter Kolkhof,So Young Kim,Faiez Zannad +9 more
TL;DR: In patients with HFrEF and moderate CKD, BAY 94-8862 5–10 mg/day was at least as effective as spironolactone 25 or 50mg/day in decreasing biomarkers of haemodynamic stress, but it was associated with lower incidences of hyperkalaemia and WRF.
Journal ArticleDOI
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos,Stefan D. Anker,Michael Böhm,Mihai Gheorghiade,Lars Køber,Henry Krum,Aldo P. Maggioni,Piotr Ponikowski,Adriaan A. Voors,Faiez Zannad,So Young Kim,Christina Nowack,Giovanni Palombo,Peter Kolkhof,Nina Kimmeskamp-Kirschbaum,Alexander Pieper,Bertram Pitt +16 more
TL;DR: Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone in patients with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus.
Journal ArticleDOI
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
Faiez Zannad,Angeles Alonso Garcia,Stefan D. Anker,Paul W. Armstrong,Gonzalo Calvo,John G.F. Cleland,Jay N. Cohn,Kenneth Dickstein,Michael J. Domanski,Inger Ekman,Gerasimos Filippatos,Mihai Gheorghiade,Adrian F. Hernandez,Tiny Jaarsma,Joerg Koglin,Marvin A. Konstam,Stuart Kupfer,Aldo P. Maggioni,Alexandre Mebazaa,Marco Metra,Christina Nowack,Burkert Pieske,Ileana L. Piña,Stuart J. Pocock,Piotr Ponikowski,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Thomas Severin,Scott D. Solomon,Kenneth M. Stein,Norman Stockbridge,Wendy Gattis Stough,Karl Swedberg,Luigi Tavazzi,Adriaan A. Voors,Scott M. Wasserman,Holger Woehrle,Andrew Zalewski,John J.V. McMurray +39 more
TL;DR: The HFA‐ESC convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework, and this report summarizes the group's recommendations for achieving common views on heart failureEndpoint selection.